DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-896 / S-012

Hoffman-LaRoche Inc
340 Kingsland Street
Nutley, NJ 07110-1199

Attention: Anne Frederick, Ph.D.
Program Manager

Dear Dr. Frederick:

Please refer to your supplemental new drug application dated November 21, 2002 submitted under section 505(b) pursuant to section 505(b)2 of the Federal Food, Drug, and Cosmetic Act for Xeloda (capecitabine) Tablets.

We acknowledge receipt of your January 3 and February 21, 2003 amendments.

This supplemental new drug application provides for addition of text under the CLINICAL PHARMACOLOGY/ Human Pharmacokinetics section in response to our October 28, 2002 letter. In addition, changes have been made to the CONTRAINDICATIONS (label and patient package insert), PRECAUTIONS and the DOSAGE AND ADMINISTRATION sections.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use a recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, and patient package insert) submitted labeling dated February 21, 2003.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-896 / S-012." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maureen Pelosi, Regulatory Project Manager, at (301) 594-5778.

Sincerely,

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

3/15/03 01:57:45 PM